Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1348-1356

  Chang, David K ^a,b,c   Jamieson, Nigel B ^j,k   Johns, Amber L ^a   Scarlett, Christopher J ^a,h   Pajic, Marina ^a   Chou, Angela ^a,d   Pinese, Mark ^a   Humphris, Jeremy L ^a   Jones, Marc D ^a   Toon, Christopher ^a   Nagrial, Adnan M ^a   Chantrill, Lorraine A ^a,i   Chin, Venessa T ^a   Pinho, Andreia V ^a   Rooman, Ilse ^a   Cowley, Mark J ^a   Wu, Jianmin ^a   Mead, R Scott ^a   Colvin, Emily K ^a   Samra, Jaswinder S ^e,f   Corbo, Vincenzo ^m   Bassi, Claudio ^m   Falconi, Massimo ^m   Lawlor, Rita T ^m   Crippa, Stefano ^m   Sperandio, Nicola ^m   Bersani, Samantha ^m   Dickson, Euan J ^j   Mohamed, Mohamed A A ^k   Oien, Karin A ^k,l   Foulis, Alan K ^k,l   Musgrove, Elizabeth A ^a   Sutherland, Robert L ^a   Kench, James G ^a,f,g   Carter, C Ross ^j   Gill, Anthony J ^a,e,f   Scarpa, Aldo ^m   McKay, Colin J ^j   Biankin, Andrew V ^a,b,c   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ Macarthur Cancer Therapy Centre   (Australia)

^j GLASGOW ROYAL INFIRMARY   (United Kingdom)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^m UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 1; MUCIN 2; TRANSCRIPTION FACTOR CDX2;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE CARCINOMA; TISSUE MICROARRAY; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; COHORT STUDIES; COMMON BILE DUCT NEOPLASMS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATIN-20; KERATIN-7; MALE; MIDDLE AGED; MUCIN-1; MUCIN-2; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS;

EID: 84876081195     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.8868     Document Type: Article

References (33)

1. Howe JR, Klimstra DS, Moccia RD, et al: Factors predictive of survival in ampullary carcinoma. Ann Surg 228:87-94, 1998 (Pubitemid 30190320)
2. Roder JD, Schneider PM, Stein HJ, et al: Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 82:1693-1696, 1995
3. Yeo CJ, Sohn TA, Cameron JL, et al: Periampullary adenocarcinoma: Analysis of 5-year survivors. Ann Surg 227:821-831, 1998 (Pubitemid 29119529)
4. Bouvet M, Gamagami RA, Gilpin EA, et al: Factors influencing survival after resection for periampullary neoplasms. Am J Surg 180:13-17, 2000
5. O'Connell JB, Maggard MA, Manunga J Jr, et al: Survival after resection of ampullary carcinoma: A national population-based study. Ann Surg Oncol 15:1820-1827, 2008
6. Albores-Saavedra J, Schwartz AM, Batich K, et al: Cancers of the ampulla of Vater: Demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 100:598-605, 2009
7. Hatzaras I, George N, Muscarella P, et al: Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol 17:991-997, 2010
8. Winter JM, Cameron JL, Olino K, et al: Clinicopathologic analysis of ampullary neoplasms in 450 patients: Implications for surgical strategy and longterm prognosis. J Gastrointest Surg 14:379-387, 2010
9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999; discussion 782-784
10. Takada T, Amano H, Yasuda H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695, 2002
11. Smeenk HG, van Eijck CH, Hop WC, et al: Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891. Ann Surg 246:734-740, 2007 (Pubitemid 350035648)
12. Lee JH, Whittington R, Williams NN, et al: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47:945-953, 2000 (Pubitemid 30345592)
13. Mehta VK, Fisher GA, Ford JM, et al: Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: Preliminary report. Arch Surg 136:65-69, 2001 (Pubitemid 32064123)
14. Sikora SS, Balachandran P, Dimri K, et al: Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol 31:158-163, 2005 (Pubitemid 40214751)
15. Bhatia S, Miller RC, Haddock MG, et al: Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 66:514-519, 2006 (Pubitemid 44332725)
16. Krishnan S, Rana V, Evans DB, et al: Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of Vater. Int J Radiat Oncol Biol Phys 70:735-743, 2008 (Pubitemid 351199709)
17. Zhou J, Hsu CC, Winter JM, et al: Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol 92:244-248, 2009
18. Kim K, Chie EK, Jang JY, et al: Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys 75:436-441, 2009
19. Westgaard A, Tafjord S, Farstad IN, et al: Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 8:170, 2008
20. Carter JT, Grenert JP, Rubenstein L, et al: Tumors of the ampulla of Vater: Histopathologic classification and predictors of survival. J Am Coll Surg 207:210-218, 2008
21. Hansel DE, Maitra A, Lin JW, et al: Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 23:1811-1818, 2005 (Pubitemid 46211359)
22. Chu PG, Schwarz RE, Lau SK, et al: Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: Application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 29:359-367, 2005 (Pubitemid 40321972)
23. Zhou H, Schaefer N, Wolff M, et al: Carcinoma of the ampulla of Vater: Comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 28:875-882, 2004 (Pubitemid 38856842)
24. Mani S, Kugler J, Knost J, et al: Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer. Invest New Drugs 16:275-278, 1998-1999 (Pubitemid 29201748)
25. Neoptolemos JP, Moore MJ, Cox TF, et al: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 308:147-156, 2012
26. Edge SB, Byrd DR, Carducci M (eds): AJCC Cancer Staging Manual. New York, NY, Springer, 2009
27. Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 13:962-972, 2000
28. Lau SK, Weiss LM, Chu PG: Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: An immunohistochemical study. Am J Clin Pathol 122:61-69, 2004 (Pubitemid 38849873)
29. Werling RW, Yaziji H, Bacchi CE, et al: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27:303-310, 2003 (Pubitemid 36245795)
30. Moskaluk CA, Zhang H, Powell SM, et al: Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol 16:913-919, 2003 (Pubitemid 37152021)
31. Yonezawa S, Higashi M, Yamada N, et al: Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci 17:108-124, 2010
32. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
33. LoRusso PM, Schnipper LE, Stewart DJ, et al: Translating clinical trials into meaningful outcomes. Clin Cancer Res 16:5951-5955, 2010